Peptide Comparison
IGF-1 LR3 vs IGF-1 DES
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
This combination is flagged
Two IGF-1 analogs in the same regimen: Moderate-High risk per peptide research literature. Multiple IGF-1 analogs compete for the same IGF-1R pool; the second analog does not raise peak receptor activation but stacks hypoglycemia exposure, cardiac/renal/hepatic hypertrophy signal, and peripheral neuropathy risk in heavy stacks.
Data-derived verdict
IGF-1 LR3 and IGF-1 DES share the igf-1 class and carry roughly equivalent evidence (Anecdotal + Animal Studies / Anecdotal + Animal Studies). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: theoretical cancer risk. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| IGF-1 LR3 | IGF-1 DES | |
|---|---|---|
| Class | IGF-1 analog (extended half-life); anabolic | IGF-1 analog (truncated); anabolic |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | IGF-1 receptor agonist; Arg3 substitution reduces IGFBP binding for prolonged activity | Truncated IGF-1 with reduced IGFBP binding for higher local receptor activity |
| Route | SC / IM | SC / IM |
| Half-life | ~20-30 hrs | ~30 min |
| Dosage (research) | 20 mcg SC daily (Seeds Vol 1 endurance and recovery starting dose, range up to 100 mcg/day for hypertrophy per r/Peptides wiki) | 50-150 mcg SC near target muscle |
| Evidence tier | Anecdotal + Animal Studies | Anecdotal + Animal Studies |
| Research depth | 34 indexed | 25 indexed |
| Availability | Research Chemical | Research Chemical |
| Reported risks | Hypoglycemia risk; theoretical cancer risk; disproportional organ/tissue growth | Hypoglycemia; localized tissue growth; theoretical cancer risk |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick IGF-1 LR3 or IGF-1 DES?
IGF-1 LR3 and IGF-1 DES share the igf-1 class and carry roughly equivalent evidence (Anecdotal + Animal Studies / Anecdotal + Animal Studies). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.
What is the difference between IGF-1 LR3 and IGF-1 DES?
IGF-1 LR3 is classed as IGF-1 analog (extended half-life); anabolic; IGF-1 DES is classed as IGF-1 analog (truncated); anabolic. Reported mechanism: IGF-1 LR3, IGF-1 receptor agonist; Arg3 substitution reduces IGFBP binding for prolonged activity; IGF-1 DES, Truncated IGF-1 with reduced IGFBP binding for higher local receptor activity. Reported half-life: IGF-1 LR3, ~20-30 hrs; IGF-1 DES, ~30 min. Routes in published studies: IGF-1 LR3, SC / IM; IGF-1 DES, SC / IM.
Which has stronger evidence, IGF-1 LR3 or IGF-1 DES?
IGF-1 LR3 and IGF-1 DES sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. IGF-1 LR3 is graded Anecdotal + Animal Studies, with 2 cited sources on its reference page and 34 indexed studies. IGF-1 DES is graded Anecdotal + Animal Studies, with 2 cited sources on its reference page and 25 indexed studies.
Which is more accessible, IGF-1 LR3 or IGF-1 DES?
Neither IGF-1 LR3 nor IGF-1 DES is an FDA-approved drug. Catalog status: IGF-1 LR3, Research Chemical; IGF-1 DES, Research Chemical.
Are IGF-1 LR3 and IGF-1 DES ever combined?
IGF-1 LR3 and IGF-1 DES appear together in no stack catalogued on PeptideHelper.org. PeptideHelper.org's interaction engine flags the pair: Two IGF-1 analogs in the same regimen, moderate-high risk.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…